Clomiphene 55mg
Clomiphene 55mg is part of a prescriber-directed hormone or endocrine protocol. It should be selected based on symptoms, diagnosis, labs when appropriate, route preference, contraindications, and ongoing monitoring.
Clomiphene 55 mg is a compounded oral capsule containing a higher prescribed dose of clomiphene citrate, a selective estrogen receptor modulator (SERM). By competitively blocking hypothalamic and pituitary estrogen receptors, clomiphene removes estradiol-mediated negative feedback and stimulates increased endogenous LH and FSH secretion. In men, this drives endogenous testosterone production while preserving HPG axis integrity and spermatogenesis. The 55 mg dose reflects prescriber customization beyond standard commercial tablet strengths for precise titration of gonadotropin stimulation. Genesis Compounding prepares this as a prescription-only 503A compounded oral preparation for patient-specific use.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Clomiphene 55mg | SERM that competitively antagonizes hypothalamic and pituitary estrogen receptors, removing negative estrogenic feedback and augmenting pulsatile GnRH/LH/FSH release to stimulate endogenous testosterone production and maintain spermatogenesis. |
Route: Oral (capsule).
- Swallow whole with or without food.
- Administer at the same time daily to maintain consistent plasma levels and hormonal stimulation.
- Do not crush or open the capsule.
This 55 mg strength is a prescriber-customized dose for this patient. General principles:
- Dosing exceeds the standard 50 mg commercial tablet and may be used when a slightly higher dose is required for adequate gonadotropin stimulation in men with secondary hypogonadism.
- Serum testosterone, LH, FSH, and estradiol guide dose titration.
- Maximum duration, frequency, and specific administration instructions are determined by the prescribing clinician.
- In male hypogonadism protocols, daily or alternate-day dosing is common.
Mechanism of action is identical to clomiphene 25 mg. Clomiphene competitively occupies hypothalamic and pituitary estrogen receptors (ERα and ERβ), preventing endogenous estradiol from binding and exerting its normal negative feedback on GnRH pulse generator activity. This disinhibition increases GnRH pulsatility, amplifying LH and FSH secretion. In men with an intact HPG axis, the resulting LH surge stimulates Leydig cell testosterone biosynthesis, while FSH supports Sertoli cell function and spermatogenesis. The 55 mg dose is expected to produce a quantitatively similar but potentially greater degree of HPG axis stimulation compared to 25 mg or 50 mg, based on prescriber assessment of patient-specific needs.
Clinical use context is the same as clomiphene 25 mg. The 55 mg strength is indicated by the prescriber when standard dosing has produced suboptimal testosterone levels or gonadotropin stimulation. This compounded strength allows incremental dose escalation beyond the available 50 mg commercial tablet without requiring patients to take more than one tablet.
Prescriber monitoring:
- Same monitoring parameters as clomiphene 25 mg: testosterone, LH, FSH, estradiol, prolactin, visual symptoms, and lipids.
- At higher doses, estradiol elevation and associated side effects (gynecomastia, mood changes) should be tracked.
- Consider aromatase inhibitor co-administration if estradiol rises excessively relative to testosterone.
Contraindications:
- Pregnancy; hepatic disease; hypersensitivity to clomiphene; uncontrolled thyroid or adrenal dysfunction; ovarian cysts of unknown etiology; endometrial carcinoma.
Warnings & Precautions:
- Visual disturbances: stop immediately and consult ophthalmology; may be irreversible.
- Estradiol excess: at higher doses, estrogen elevation may cause gynecomastia, mood changes, and water retention; monitor E2 levels.
- OHSS risk in women; multiple gestation risk.
- Hepatotoxicity risk; avoid in liver disease.
Drug Interactions:
- No established significant drug-drug interactions; review all concurrent medications with the prescriber.
Common Side Effects: Hot flashes; headache; dizziness; nausea; visual disturbances; breast tenderness or gynecomastia; mood alterations; ovarian enlargement (women).
Store at controlled room temperature (20–25°C / 68–77°F). Protect from moisture and light. Keep tightly sealed. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.
Why is this capsule 55 mg instead of the standard 50 mg tablet?
Standard commercially available clomiphene tablets come in 50 mg increments. Compounding allows the prescriber to customize the dose to 55 mg for precision titration—delivering a specific, individualized amount beyond what commercial formulations permit. This approach is one of the key advantages of 503A compounding for hormone management.
How does 55 mg differ from 50 mg in effect?
The incremental 5 mg difference is modest but clinically meaningful for dose-sensitive patients whose testosterone response requires fine adjustment. Your prescriber will assess your hormone levels to confirm whether this dose achieves the target range.
Is this product FDA-approved?
No. This compounded 55 mg clomiphene capsule is a 503A prescription preparation from Genesis Compounding for a specific patient. Clomiphene is FDA-approved for anovulatory infertility in women; use in male hypogonadism is off-label at any dose.
What if I experience visual changes?
Discontinue immediately and contact your prescriber and an ophthalmologist. Visual disturbances (blurred vision, scotoma, light sensitivity) are a warning sign that requires prompt evaluation and cessation of treatment.
How will I know this dose is working?
Your prescriber will monitor serum total testosterone, LH, FSH, and estradiol to evaluate HPG axis response. Symptomatic improvement in energy, libido, and mood typically follows normalization of testosterone levels, usually within 4–8 weeks of dose stabilization.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.